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The schizophrenia risk allele C of the TCF4 rs9960767
polymorphism disrupts sensorimotor gating in schizophrenia
spectrum and healthy volunteers
Abstract
In a large-scale meta-analysis, it has been recently shown that the transcription factor 4 (TCF4) gene is
among the most prominent susceptibility genes for schizophrenia. Moreover, transgenic mice
overexpressing TCF4 in the brain display a reduction of sensorimotor gating measured by prepulse
inhibition (PPI) of the acoustic startle response (ASR). PPI is heritable and has been established as an
important translational endophenotype of schizophrenia. We therefore investigated the impact of the
schizophrenia susceptibility gene TCF4 (rs9960767) on sensorimotor gating of the ASR in healthy
humans and in patients with a schizophrenia spectrum disorder. We assessed PPI, startle reactivity, and
habituation of the ASR in two independent samples. The first sample consisted of 107 healthy
volunteers from London, UK. The second sample was a schizophrenia spectrum group (n = 113) of 73
schizophrenia patients and 40 individuals at high risk for schizophrenia from Bonn, Germany (total
sample n = 220). In both samples, PPI was strongly decreased in carriers of the schizophrenia risk allele
C of the TCF4 gene (meta-analysis across both samples: p = 0.00002), whereas startle reactivity and
habituation were unaffected by TCF4 genotype. Sensorimotor gating is modulated by TCF4 genotype,
indicating an influential role of TCF4 gene variations in the development of early
information-processing deficits in schizophrenia.
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In a large-scale meta-analysis, it has been recently shown that the transcription factor 4 (TCF4) gene is among the most prominent
susceptibility genes for schizophrenia. Moreover, transgenicmice overexpressing TCF4 in the brain display a reduction of sensorimotor
gating measured by prepulse inhibition (PPI) of the acoustic startle response (ASR). PPI is heritable and has been established as an
important translational endophenotype of schizophrenia. We therefore investigated the impact of the schizophrenia susceptibility gene
TCF4 (rs9960767) on sensorimotor gating of the ASR in healthy humans and in patients with a schizophrenia spectrum disorder. We
assessed PPI, startle reactivity, and habituation of the ASR in two independent samples. The first sample consisted of 107 healthy
volunteers from London, UK. The second sample was a schizophrenia spectrum group (n 113) of 73 schizophrenia patients and 40
individuals at high risk for schizophrenia from Bonn, Germany (total sample n 220). In both samples, PPI was strongly decreased in
carriers of the schizophrenia risk allele C of the TCF4 gene (meta-analysis across both samples: p 0.00002), whereas startle reactivity
andhabituationwere unaffected byTCF4 genotype. Sensorimotor gating ismodulated byTCF4 genotype, indicating an influential role of
TCF4 gene variations in the development of early information-processing deficits in schizophrenia.
Introduction
Although schizophrenia is a strongly inherited disease with a her-
itability of 80% or more, the genetic basis of this disease is still
elusive. A recentmeta-analysis across SNP data from several large
genomewide scans revealed that the risk of schizophrenia was
significantly associated with a marker in intron four of the tran-
scription factor 4 (TCF4) gene on chromosome 18q21.2 (Ste-
fansson et al., 2009). Interestingly, a translational animal study
recently showed that transgenic mice that moderately overex-
press TCF4 postnatally in the brain display profound reductions
in sensorimotor gating (Brzo´zka et al., 2010)—an established
translational and behavioral endophenotype of schizophrenia
(Gottesman and Gould, 2003). TCF4 is a class I basic helix-loop-
helix (bHLH) protein that is involved in the development of the
mammalian CNS. Although TCF4 shows sustained expression in
several brain regions throughout lifetime, its function in the adult
CNS remains widely unclear (Soosaar et al., 1994; Flora et al., 2007).
Sensorimotor gating is commonly operationalized by pre-
pulse inhibition (PPI) of the acoustic startle response (ASR). PPI
is defined as a substantial reduction of the startle amplitude that
occurs when a distinctive nonstartling stimulus is presented 30–
500 ms before the startling stimulus (Graham, 1975). PPI is reg-
ulated by a cortico-striato-pallido-pontine (CSPP) circuitry
including frontal and mediotemporal regions, ventral striatum,
ventral pallidum, and pontine regions of the brainstem (Fendt et
al., 2001; Swerdlow et al., 2001). Several neuropsychiatric disor-
ders present diminished PPI (Braff et al., 2001), but this is most
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strongly evident in schizophrenia spectrumdisorders (Braff et al.,
1992; Cadenhead et al., 1993; Kumari et al., 2000; Parwani et al.,
2000; Ludewig et al., 2003). Furthermore, PPI is heritable
(Anokhin et al., 2003; Greenwood et al., 2007), reduced in unaf-
fected relatives of schizophrenia patients (Cadenhead et al., 2000;
Kumari et al., 2005a), influenced by SNPs within the dopamine,
acetylcholine, and serotonin system (Quednow et al., 2008b,
2009, 2010; Roussos et al., 2008a,b; Petrovsky et al., 2010) and
already decreased during the prodromal stage of schizophrenia
(Quednow et al., 2008a), suggesting that PPI is an important and
valid candidate as an intermediate or endophenotypic marker in
genetic studies of schizophrenia (Gottesman and Gould, 2003).
Based on the recent finding that the TCF4 SNP rs9960767 is a
genetic risk factor for schizophrenia, that transgenic mice over-
expressing TCF4 show reduced sensorimotor gating, and that
sensorimotor gating is an established endophenotypeof schizophre-
nia, we hypothesized that human carriers of the schizophrenia risk
allele C of the TCF4 rs9960767 SNP would exhibit decreased
sensorimotor gating. To avoid spurious results, we investigated
two independent European Caucasian samples—a sample of 107
healthy volunteers recruited inUnitedKingdom, and a combined
sample of 73 schizophrenia inpatients and 40 individuals at high
risk for schizophrenia recruited in Germany, to directly test for
replicability of our findings. This allowedus to explore the impact
of this SNP in a sample of healthy subjects with a normal expres-
sion of the PPI endophenotype as well as in a schizophrenia spec-
trum sample with a known alteration of the endophenotype.
Materials andMethods
Participants. For the first sample, 107 healthy Caucasian volunteers (54
males, 53 females) with self-reported grandparents of European origin
were recruited through local advertisements in South London, United
Kingdom. Participants aged between 18 and 45 years were screened for
the exclusion criteria of DSM-IV Axis I disorders using the Structured
Clinical Interview for DSM-IV Disorders for healthy subjects (SCID-
NP). Additional exclusion criteria were a history of head injuries, any
known neurological abnormalities or systemic illness with known
neurological complication, a first-degree relative with psychosis or
obsessive-compulsive disorder, and a history of substance abuse or de-
pendence. Current smoking behavior was assessed with the Fagerstro¨m
Test for Nicotine Dependence (Heatherton et al., 1991) and the number
of cigarettes smoked per day (CPD).
For the second sample, 73 inpatients (50 males, 23 females) admitted
to the psychiatric hospital of the University of Bonn, Germany, with a
diagnosis of schizophrenia according to DSM-IV were included. More-
over, 40 subjects with symptoms indicating high risk for schizophrenia
(23 males, 17 females) were recruited as described in detail previously
(Ha¨fner et al., 2004; Quednow et al., 2008a; Frommann et al., 2010).
Patients and high-risk individuals were included if they were of Cauca-
sian ethnicity with self-reported grandparents of European origin and
aged between 18 and 65 years. Exclusion criteria were a history of head
injuries, a neurological disease, a history of substance abuse or depen-
dency, or a severe somatic disease. Every participant was evaluated with
the Structured Clinical Interview (SCID-I). Clinical symptoms were
measured with the Positive and Negative Syndrome Scale (PANSS) (Kay
et al., 1992). Fourteen schizophrenia patients were never medicated
(these patients experienced a first episode of psychosis), 12 patients re-
ceived a typical antipsychotic, 43 patients were treated with an atypical
antipsychotic, 3 received two atypical drugs, and 1 received a typical and
an atypical antipsychotic. Four high-risk individuals received treatment
with atypical antipsychotics. From schizophrenia patients, urine toxicol-
ogies were obtained before inclusion to rule out active substance abuse.
The total (healthy and schizophrenia spectrum) sample consists of 220
individuals. For both samples, ethical approvals of the local ethics com-
mittees were obtained, and all participants provided written informed
consent before inclusion.
Genotyping. In the healthy volunteers from London, DNA concentra-
tion from cheek swabs or from EDTA acid anticoagulated blood was
adjusted using the PicoGreen quantitation reagent (Invitrogen) and 1 ng
was genotyped using the iPLEX assay on the MassARRAY MALDI-TOF
mass spectrometer (SEQUENOM). Genotyping was successful in 93.5%
of subjects. To check for genotyping errors, CEU families were genotyped
too with a 100% concordance rate. Furthermore, genotype frequency of
the TCF4 rs9960767 SNP in the London sample (AA: 87.8%, AC: 10.2%,
CC: 2%; A-allele: 92.9%, C-allele: 7.1%) was very similar as in the
HapMap-CEU population available at the NCBI website (AA: 88.3%,
AC: 10.0%, CC: 1.7%; A-allele: 93.3.%, C-allele: 6.7%; www.hapmap.
org) and distributed in accordance with the Hardy–Weinberg Equilib-
rium (HWE) ( p 0.07).
In the German schizophrenia patients and high-risk individuals, DNA
for genotyping was isolated either from EDTA acid anticoagulated blood
or permanent cell cultures received after transforming the lymphocytes
with Epstein–Barr virus. The isolation of theDNA followed theQIAGEN
protocol for the Blood & Cell Culture DNA Maxi Kit (QIAGEN). PCR
was performed using 12.5 ng of DNA. The TCF4 SNP (rs9960767) was
analyzed by a TaqMan assay (Applied Biosystems). Genotyping was suc-
cessful in 97.3%of subjects. For quality control, the complete sample was
genotyped twice. Concordance among duplicate samples was 100%. Ge-
notype frequency of the TCF4 SNP in the Bonn sample (AA: 89.5%, AC:
10.5%, CC: 0%; A-allele: 94.8%, C-allele: 5.2%) was also comparable to
the HapMap-CEU population (see above) and as well distributed in
accordance with HWE ( p 1.0).
Startle response measurement. The two samples were assessed with the
same hardware but with slightly different PPI paradigms. In the London
sample, we used three stimulus onset asynchronies (SOAs) of 30, 60, and
120 ms between the prepulse and the pulse alone (PA), while we used
only a single SOA condition in the Bonn sample (120 ms). Equipment,
setup, PPI testing, and data acquisition and scoring procedures for both
methods have previously been described in detail [London sample: Ku-
mari et al. (2005b); Bonn sample: Quednow et al. (2006a,b, 2008a)]. In
both centers, we used the SRRED2 software (San Diego Instruments) to
analyze the startle data. According to Braff et al. (1992), the latency to
startle response onset was defined by a shift of six digital units from the
baseline value occurring between 21 and 120 ms after the acoustic startle
stimulus. Latency to response peak was defined as the point of maximal
amplitude that occurred within 150 ms after the startle stimulus. Re-
sponse rejections were made in case of onset-to-peak latencies95 ms,
onset latencies100ms, and baseline shifts90 digital units (e.g., due to
spontaneous or voluntary blinks). Subjects with response rejections
50%were excluded from data analysis (healthy subjects: n 2; schizo-
phrenia patients: n  3; high-risk individuals: n  2). All remaining
subjects showed a mean startle amplitude 25 units—the commonly
used threshold for analyzable startle data (Braff et al., 1992).
Themean percentage PPI of startle amplitude was calculated using the
following formula: %PPI 100 (amplitude on PA trials amplitude
on prepulse trials)/amplitude on PA trials (Braff et al., 1992). For the
assessment of startle habituation, PA trials were each divided into four
blocks in the British sample and in six blocks in the German sample. The
calculation of the habituation measures (early and late habituation in
percentage, and linear gradient coefficient b) has been described in detail
previously (Quednow et al., 2006a,b). Startle reactivity was assessed by
themean amplitude of the first block of PA trials and themean amplitude
of all PA trials.
Statistical analysis. Given that the minor allele frequency of the TCF4
rs9960767 SNP is relatively low (6%) (Stefansson et al., 2009), we
compared only homozygous carriers of the A-allele with carriers of the
schizophrenia risk allele C (AA vs ACCC). All demographic data were
analyzed by ANOVA with the exception of frequency data. Frequency
data were analyzed using Fishers exact  2 test. Given that sex, smoking,
and antipsychotic medication might affect PPI (Swerdlow et al., 1997;
Kumari and Gray, 1999; Swerdlow et al., 2006), these variables were
introduced as covariates in analyses of covariance (ANCOVA) of PPI
data independent of the statistical significance of the covariates. All other
psychophysiological parameters were analyzed with ANOVA. The con-
firmatory statistical comparisons were performed at a significance level
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set at p 0.05 (two-tailed). Within the Pearson product-moment corre-
lation analyses, the significance level was set at p  0.01 (two-tailed) to
avoid accumulation of -error. Effect size calculations between two
groups refer to Cohen’s d. For meta-analysis of the genotype effects on
PPI across both samples, we used Stouffer’s z-trend method and Fisher’s
trend to combine p values (Whitlock, 2005), and the weighted integra-
tion method as well as a random-effects model according to Hedges and
Olkin to combine effect sizes (Hedges andOlkin, 1985); Armitage’s trend
test was used to analyze associations between the TCF4 SNP and schizo-
phrenia (Armitage, 1955).
Results
London sample (healthy volunteers)
The two genotype groups (homozygous AA-carriers vs C-allele
carriers) did not differ regarding age, sex, years of education
(YoE), habituation, and startle reactivity (Table 1). However,
there was not a single smoker in the C-allele group and, therefore,
we compared the C-allele group with nonsmoking homozygous
AA-carriers in additional analyses (see below).
PPI was strongly affected by TCF4 genotype: carriers of the
schizophrenia risk allele C display decreased PPI levels (Table 1,
Fig. 1A). A 3  2 (SOA condition  genotype) repeated-
measures ANCOVA with sex and CPD as covariates revealed
significant main effects for the factors SOA condition (F(2,188)
11.4, p  0.001, p 2  0.11), sex (F(1,94)  7.5, p  0.01, p 2 
0.07), and genotype (F(2,94) 11.2, p 0.001,p 2 0.11).More-
over, there was a significant interaction of the factors SOA and
genotype (F(2,188)  3.0, p  0.05, p 2  0.03), indicating a dif-
ferential impact of genotype on the SOA conditions. ANCOVA
post hoc test across SOA conditions (corrected for sex and CPD)
revealed that the genotype effect was most pronounced in the
SOA120ms PPI condition (SOA30: F(1,94) 7.4, p 0.01,p 2
0.07; SOA 60: F(1,94) 4.1, p 0.05,p2 0.04; SOA 120: F(1,94)
14.5, p 0.001, p 2 0.14). The main effect of SOA reflects the
well known nature of PPI to increase with rising SOA from 30ms
through 120 ms (Blumenthal, 1999). The effect of sex reflects the
known fact that women have generally lower PPI levels thanmen
(pooled SOA conditions: F(1,103) 10.8, p 0.001, p 2 0.10)
(Swerdlow et al., 1997).
To exclude a potential impact of smoking on our results, we
repeated the PPI analyses after exclusion of smokers (12 CC/AC
carriersvs63AAcarriers).However,PPIwas still stronglyaffectedby
TCF4 genotype. A 3  2 (SOA condition  genotype) repeated-
measures ANCOVA with sex as a covariate still revealed significant
main effects for the factors SOA condition (F(2,144) 7.3, p 0.001,
p2 0.09), sex (F(1,72) 6.4, p 0.05, p2 0.08), and genotype
(F(1,72)8.8,p0.01,p20.11).The significantSOAgenotype
also remained true (F(2,144)  3.4, p  0.05, p 2  0.05). The
ANCOVA post hoc tests across SOA conditions showed the same
effects (SOA30:F(1,72) 6.7, p 0.05,p2 0.09; SOA60:F(1,72)
3.1, p 0.08,p2 0.04; SOA 120: F(1,72) 11.8, p 0.001,p2
0.14). Introduction of startle amplitude as a covariate also did not
change our results. Age, smoking parameters, and YoE did not sig-
nificantly correlate with any of the psychophysiological parameters.
Bonn sample (schizophrenia patients and high-risk
individuals)
The genotype groups did not differ regarding age, sex, smoking
status, medication, and number of high-risk individuals (Table
2). There was a moderate effect of genotype on YoE (d  0.48),
suggesting a possible effect of TCF4 genotype on intellectual
functioning at least in schizophrenia patients and subjects at risk
for schizophrenia (Table 2).
The association between PPI and TCF4 genotype was con-
firmed in the Bonn sample. Again, carriers of the schizophrenia
Table 1. Demographic data and psychophysiological parameters of healthy volunteers from London, UK, grouped according to their TCF4 rs9960767 genotype (means and
SEMs in parentheses, sex and smoking status in frequency data)
TCF4 rs9960767 genotype CC AC AA Total F df/dferr p d
a p 2
n 12 (12.2%) 86 (87.8%) 98 (100%)
Age 25.4 (1.7) 26.2 (0.7) 26.1 (0.6) 0.20 1/97 0.66 0.13 0.00
Years of education 17.2 (1.2) 17.2 (0.3) 17.2 (0.3) 0.00 1/97 1.00 0.00 0.00
Male (%)b 33.3% 51.2% 49.0% — 1 0.36 — —
Current smokers (%)b 0.0% 26.7% 23.5% — 1 0.06 — —
Current cigarettes smoked per day
(only in smokers)
— 9.0 (1.3), n23 9.0 (1.3), n23 — — — — —
Fagerström Nicotine Dependence
Test (score; only in smokers)
— 1.8 (0.5), n23 1.8 (0.5), n23 — — — — —
First block, amplitude of pulse-alone
trials (arbitrary units)
685 (160) 706 (41.9) 703 (41.3) 0.03 1/97 0.87 0.05 0.00
Mean amplitude of pulse-alone trials
(arbitrary units)
523 (117) 579 (38.6) 572 (36.6) 0.25 1/97 0.62 0.15 0.00
Mean PPI (%; mean across 3 SOA
conditions: 30, 60, 120 ms)c
14.4% (4.9) 32.9% (1.7) 30.8% (1.7) 12.8 1/93 0.001 1.07 0.12
Early habituation of pulse-alone
trials (%; between first and
second block)
25.9% (8.3) 19.6% (2.9) 20.4% (2.7) 0.59 1/97 0.45 0.24 0.01
Total habituation of pulse-alone
trials (%; between first and fourth
block)
29.2% (11.9) 28.9% (3.3) 28.9% (3.3) 0.00 1/97 0.97 0.01 0.00
Habituation of pulse-alone trials
across 4 blocks (linear gradient
coefficient b)
81.3 (28.9) 65.0 (8.6) 67.0 (8.3) 0.41 1/97 0.52 0.20 0.00
Bold indicates statistical significance.
aEffect size Cohen’s d (d 0.2 is small, d 0.5 is moderate, and d 0.8 is a strong effect).
bFisher’s exact test.
cANCOVA, means adjusted by covariates sex and cigarettes per day.
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risk allele C revealed lower PPI levels (Table 2, Fig. 1B). An
ANCOVA with sex, smoking status, and antipsychotic medica-
tion status as covariates revealed a significant main effect of ge-
notype onPPI (F(1,100) 5.1, p 0.05,p 2 0.05). The influence
of the covariate smoking status was not significant (F(1,100) 3.1,
p  0.08, p 2  0.03). Introduction of chlorpromazine equiva-
lents as a covariate instead of medication status revealed a similar
genotype effect (F(1,100) 4.6, p 0.05, p 2 0.05). Given that
especially atypical antipsychotics could normalize PPI (e.g., Ku-
mari et al., 2000), we also excluded patients treated with atypical
antipsychotics from analysis. Despite the limited power of the
remaining sample (AA: n 55, CC AC: n 6), the genotype
effect was still significant, while the effect size was improved
(F(1,57)  4.11, p  0.05, p 2  0.07). Thus, medication effects
could not explain our findings. Moreover, introduction of startle
amplitude as a further covariate also did not change our results.
When the factor patient group (high-risk individuals vs
schizophrenia patients) was introduced as a further fixed factor
into the ANCOVA, the effect of genotype remained significant
(F(1,99)  4.3, p  0.05, p 2  0.04), while neither the factor
patient group (F(1,99)  0.74, p  0.39, p 2  0.01) nor the
genotype  patient group interaction (F(1,99)  0.15, p  0.70,
p 2  0.00) were significant. Clinical data were not affected by
TCF4 genotype. PPI did not correlate with any clinical or demo-
graphic data.
Due to the methodological differences, the Bonn schizophre-
nia spectrum sample and the London controls could not be di-
rectly compared regarding startle parameters and PPI. However,
in line withmany previous studies, the total group of schizophre-
nia patients and high-risk individuals revealed significantly de-
creased PPI levels when compared with an equivalent group of
healthy controls [t(131)  2.8, p  0.006, controls: 58.1% PPI
(SEM3.3), n 28], whowere assessed in Bonnwith the same PPI
paradigm in a previous study (Quednow et al., 2008a).
Meta-analysis of TCF4 genotype effect on PPI
To assess the total effect of TCF4 genotype on PPI across both
samples, we applied several meta-analytic approaches (Table 3).
The significance level ranged between 0.0002 and 0.00002 de-
pending on the method used. In general, meta-analytical meth-
ods combining effect sizes generated lower p values thanmethods
combining p values. Themean effect size of the genotype effect on
PPI was d 0.90.
Association between TCF4 genotype, PPI, and schizophrenia
To assess the association between the reduced PPI levels and
TCF4 rs9960767 genotype, classical odds ratios were calculated
(Bland and Altman, 2000). If a clinical criterion of 1.0 SD is
applied to define a low PPI level, reduced PPI shows a significant
association with the schizophrenia risk allele of the TCF4 SNP
within both samples (Table 4). If a more conservative criterion of
1.5 SD is applied as a criterion for diminished PPI, previously
significant associations within the London sample and the com-
bined sample still showed marked statistical trends regarding an
association. The sex distribution in the 1.0 and 1.5 SD sub-
groupswas not statistically different from the total sample (across
both samples: no criterion: 44.3%, 1.0 SD: 48.3%, 1.5 SD: 43.9%
females). Thus, this effect could not be attributed to an accumu-
lation of females in the low PPI subgroups.
There was no significant association ofTCF4 rs9960767 geno-
type with a diagnosis of schizophrenia (Armitage trend test for
the TCF4 C-allele: common odds ratio  0.71, 2  0.92; p 
0.34). However, given that the sample size was rather small and
possible effects of population stratification, this result should be
interpreted with caution.
Discussion
The present study is the first to investigate the influence of the
schizophrenia risk gene TCF4 rs9960767 on an established endo-
phenotype of schizophrenia. In two independent samples, we
could convincingly demonstrate that the schizophrenia risk allele
C of the TCF4 rs9960767 SNP is strongly associated with reduced
sensorimotor gating. In a meta-analysis of the largest genome-
wide association study to date, consisting of 12,945 schizophrenia
cases and 34,591 controls, this TCF4 SNP was among the most
statistically significant findings (Stefansson et al., 2009). The pos-
sible role of TCF4 genes in the development of schizophrenia was
lately confirmed in a large sample of Han Chinese, in which a
neighboring SNP was shown to have an impact on schizophrenia
risk (Li et al., 2010). In accordancewith recent animal data, show-
ing that transgenic mice overexpressing the TCF4 gene in the
brain display decreased sensorimotor gating (Brzo´zka et al.,
2010), this finding suggests that TCF4 plays an important role in
the development of early information deficits in schizophrenia at
least in a subgroup of patients who display diminished PPI.
The role ofTCF4 (also known asE2–2, SEF-2,ME-2, or ITF-2)
in the brain and the functional activity of the investigated TCF4
variant on the level of gene expression are not fully understood
Figure 1. The effects of TCF4 rs9960767 genotype on percentage PPI of the acoustic startle
response (means and SEM, adjusted for sex and smoking) in 98 British healthy human volun-
teers (ANCOVAcorrected for sex and smoking: ***p0.001;A) and in a combined sample of 68
schizophrenia patients and37 individuals at high risk for schizophrenia fromGermany (ANCOVA
corrected for sex, smoking, and antipsychotic medication: *p 0.05; B). SOA30, SOA60, and
SOA120, Stimulus onset asynchrony of 30, 60, and 120ms, respectively, between prepulse and
pulse alone.
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yet, but bHLH transcription factors such asTCF4 seem to play an
important role in the development of the mammalian cortex as
neuronal progenitors (Ross et al., 2003; Flora et al., 2007). TCF4
belongs to a subfamily of bHLH transcriptional regulators that
recognizes the Ephrussi-box (“E-box”) binding site on the DNA
that usually lies upstream of a gene in a promoter region (Zweier
et al., 2007). At early developmental stages, E-box transcription
factors such as TCFE2a, TCF12, and TCF4 show wide expression
throughout the brain, but only TCF4 displays sustained expres-
sion in the adult brain of mice, which is most prominent in the
cerebellum, hippocampus, and cortex (Soosaar et al., 1994; Uit-
tenbogaard and Chiaramello, 2000; Brzo´zka et al., 2010).
TCF4-null knock-out mice die in the first 24 h after birth
(Zhuang et al., 1996; Flora et al., 2007), and haploinsufficiency of
the TCF4 gene in humans causes the Pitt–Hopkins syndrome
(Zweier et al., 2007; de Pontual et al., 2009)—a neurodevelop-
mental disease characterized by severe mental retardation, mi-
crocephaly, epilepsy, facial dysmorphisms, and intermittent
hyperventilation, suggesting that TCF4 is critical for the develop-
ment of themammalian nervous system. It was recently shown in
TCF4 knock-out mice that TCF4 plays a unique role especially in
the development of the pontine nuclei (Flora et al., 2007). These
nuclei are highly interconnected with the pedunculopontine and
laterodorsal tegmental nuclei, the caudal pontine reticular nu-
cleus, and the superior colliculus (Vertes et al., 1986; Redgrave et
al., 1987; Woolf and Butcher, 1989), which are critical core re-
gions within the CSPP circuitry processing PPI of ASR (Koch,
1999; Fendt et al., 2001; Swerdlow et al., 2001). Although the
influence of pontine nuclei on PPI has not been studied so far,
one might speculate that developmental changes in these nuclei
caused by TCF4 mutations are possibly associated with func-
tional alterations of connections to neighboring brainstemnuclei
as well as of the cortico-ponto-cerebellar integration of sensori-
motor information. This assumption is also supported by the fact
that, in the London sample, PPI was strongly affected by TCF4
genotype across the entire range of SOA conditions—from the
“preconscious” 30 ms SOA to the “conscious” 120 SOA. This
pattern suggests that TCF4 genotype probably influences PPI at
an early level of information processing. The role of TCF4 in
sensorimotor gating could be further investigated by studying
PPI in patientswith Pitt–Hopkins syndrome (Zweier et al., 2007).
However, this mutation is rare and the recruitment of a suffi-
cient sample size as well as the matching would be a demand-
ing exercise.
In the meantime, numerous association studies in healthy
humans and schizophrenia patients suggest that PPI is influ-
enced by several genetic variations. It was shown that SNPs
of the serotonin-2A receptor (5-HT2AR), the catechol-O-
methyltransferase (COMT), the dopamine D3 receptor, and the
3 subunit of nicotinic acetylcholine receptor (CHRNA3)may all
reliably affect PPI (Quednow et al., 2008b, 2009, 2010; Roussos et
Table 2. Demographic data and psychophysiological parameters of a combined sample of 68 schizophrenia patients and 37 individuals at high risk for schizophrenia from
Bonn, Germany, grouped according to their TCF4 rs9960767 genotype (means and SEMs in parentheses, sex and smoking status in frequency data)
TCF4 rs9960767 genotype CC AC AA Total F df/dferr p d
a p 2
n 11 (10.5%) 94 (89.5%) 105 (100%)
Age 34.0 (4.1) 31.6 (1.0) 31.9 (1.0) 0.55 1/104 0.46 0.24 0.01
Years of education 13.4 (0.7) 14.8 (0.3) 14.6 (0.3) 2.28 1/104 0.13 0.48 0.02
Men (%)b 45.5% 63.8% 61.9% — 1 0.33 — —
Current smokers (%)b 63.6% 45.7% 47.6% — 1 0.34 — —
High-risk subjects (%)b 45.5% 34.0% 35.2% — 1 0.51 — —
Medication status (%; never-medicated/
typical/atypical antipsychotic)b
45.5/9.1/45.5% 47.9/10.6/41.5% 47.6/10.5/41.9% — 2 0.97 — —
Daily chlorpromazine equivalentsc 205 (64.0) 166 (23.0) 171 (21.6) 0.32 1/104 0.57 0.18 0.00
PANSS Positive 16.3 (2.3) 15.5 (0.9) 15.6 (0.8) 0.09 1/104 0.76 0.10 0.00
PANSS Negative 18.8 (3.0) 17.9 (0.9) 17.9 (0.8) 0.11 1/104 0.75 0.11 0.00
PANSS General 36.8 (4.8) 36.8 (1.5) 36.8 (1.4) 0.00 1/104 1.00 0.00 0.00
PANSS Total 71.9 (9.6) 70.6 (2.9) 70.7 (2.8) 0.02 1/104 0.89 0.05 0.00
First block, amplitude of pulse-alone trials
(arbitrary units)
384 (74.9) 306 (21.0) 314 (20.3) 1.38 1/104 0.24 0.37 0.01
Mean amplitude of pulse-alone trials
(arbitrary units)
291 (64.1) 232 (18.7) 238 (18.0) 1.00 1/104 0.32 0.32 0.01
Mean percentage PPI (SOA 120 ms)d 25.0% (8.4) 45.2% (2.9) 42.6% (2.7) 5.13 1/100 0.03 0.73 0.05
Percentage early habituation of pulse-alone
trials (between first and second block)
24.8% (4.4) 22.3% (3.1) 22.6% (2.8) 0.07 1/104 0.79 0.09 0.00
Percentage total habituation of pulse-alone
trials (between first and sixth block)
32.9% (7.6) 42.1% (3.0) 41.1% (2.8) 1.06 1/104 0.31 0.33 0.01
Habituation of pulse-alone trials across 6
blocks (linear gradient coefficient b)
19.1 (5.1) 20.1 (1.9) 20.0 (1.8) 0.03 1/104 0.86 0.05 0.00
Bold indicates statistical significance.
aEffect size Cohen’s d (d 0.2 is small, d 0.5 is moderate, and d 0.8 is a strong effect).
bFisher’s exact test.
cUnmedicated patients and high-risk individuals received the value 0.
dANCOVA, means adjusted by covariates sex, medication (medicated/unmedicated), and smoking status (yes/no).
Table 3. Different meta-analytical approaches to assess TCF4 rs9960767 genotype
effects onmean percentage PPI across both investigated samples healthy
volunteers from London, UK (n 96), and a schizophrenia spectrum sample from
Bonn, Germany (n 105)	
Effect size Z p value
Fisher’s trend — — 0.0002
Stouffer’s z trend method — — 0.0001
Weighted integration methoda d 0.94 4.12 0.00002
Random-effects modela Delta 0.94 4.12 0.00002
aAccording to Hedges and Olkin (1985).
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al., 2008a,b; Petrovsky et al., 2010), which parallels well the neural
circuitry that underlies and supports PPI of the ASR (Swerdlow
and Koob, 1987; Koch, 1999; Fendt et al., 2001; Swerdlow et al.,
2001). Thus, it is most likely that each of these genetic polymor-
phisms contributes a small fraction to the variant expression of
PPI in the population. If PPI is an appropriate endophenotype of
schizophrenia, as has been proposed, a combination of these
SNPs might also contribute to the risk for schizophrenia. Never-
theless, it is not known at present whether and how these SNPs
may interact with regard to sensorimotor gating, as the sample
sizes investigated so far (250 subjects) were not suitable to in-
vestigate the interactive and epistatic effects even of two SNPs
with moderate minor allele frequencies. Further studies with
larger sample sizes (500) are needed to reliably examine
these effects. However, since very few schizophrenia patients
seem to share identical genomic causation (Need et al., 2009),
reduced PPI most likely also arises from several independent
genetic variations.
In our samples, schizophrenia was not associated with TCF4
genotype, as was previously shown (Stefansson et al., 2009).
However, our sample sizes were too small and had power too low
to detect common, relatively low-risk variants such as TCF4,
which shows ameanodds ratio of 1.23 (confidence interval: 1.15–
1.32) in a largemeta-analysis (Stefansson et al., 2009). Moreover,
the two samples were recruited in different European countries,
limiting the direct comparability because of possible population
stratification effects, which were not statistically controlled by a
standard panel of ancestry-informative SNPs. However, the in-
vestigation of the association of TCF4 and schizophrenia was not
the focus of the present study. Interestingly, low PPI levels have
shown stronger associations with the TCF4 risk allele C than
schizophrenia per se: depending on the criterion for decreased
PPI (1 or 1.5 SD below normal), odds ratios of 2.38 and 4.81 were
calculated for the entire sample (Table 4). When considering the
effect size measures according to Cohen (1988), a similar pattern
arises: In the meta-analysis, the association of a diagnosis of
schizophrenia with TCF4 genotype displayed only a very small
effect size of w  0.09 (Stefansson et al., 2009). In contrast, the
association of the schizophrenia endophenotype PPI with TCF4
showed a strong effect size of d  0.90 averaged across both
samples. Thus, the endophenotype approach could boost the
power of a genetic study compared with the approach of classical
categorization of the mental illness using the current diagnostic
manuals. Furthermore, given that TCF4 genotype was signifi-
cantly associated with PPI reduction, a combination of TCF4
genotype status and low PPI levels might be a promising marker
for the early detection of schizophrenia.
The study has some limitations. (I) The total size of our sam-
ples seems to be modest. However, compared to other studies in
the field, our study with a sample size of n 203 still belongs to
the best-powered PPI genetics studies. In contrast to many other
association studies, we recruited a highly homogeneous sample
regarding ethnicity because we only included Caucasians from
Middle Europe with self-reported grandparents of Middle Euro-
pean origin. Thus, we have a modest but clear and well selected
sample, whichmight be preferable compared to ethnically mixed
but larger samples.
(II) Are the sample sizes of subjects carrying the C-allele too
low for a reliable estimation of the group PPI levels? We do not
assume this for three reasons: (1) We tested two independent
samples as we aimed to obtain an internal replication of our
results especially to avoid spurious results. The replication of the
initial results in an independent sample makes it statistically
highly unlikely that both results could be accidental or spurious.
(2) To estimate the strength of the results, we conducted several
meta-analyses with different approaches (Table 3). They all re-
vealed a very strong genotype effect of the investigated TCF4 SNP
on PPI across both samples ( p 0.0001–0.00002,meanCohen’s
d 0.90), which is the strongest genotype effect on PPI that has
been shown across more than one tested sample so far. (3) In
total, we have 23 subjects carrying the C-allele, which is sufficient
for a reliable estimation of the mean PPI of a group. Of these 23
subjects, 14 (61%) displayed decreased PPI levels, when com-
pared to the total sample (Table 4), which is again an expression
of the strong genotype effect of TCF4 on PPI. Moreover, most of
the positive results of previous genetic PPI studies are based on
comparable or smaller SNP subgroups (e.g., Hong et al., 2008;
Quednow et al., 2008b, 2009, 2010; Roussos et al., 2008a,b). Thus,
compared to the field of PPI genetics (as well as compared to
many clinical PPI studies), a total of 23 risk allele carriers should
be sufficient for a reliable and valid estimation of the mean PPI
levels.
(III) The two independent samples were assessed with slightly
different PPI paradigms, which preclude the direct comparison
of the samples regarding PPI. Therefore, we decided to analyze
the genotype effects only within each sample and to subsequently
pool the p values and effect sizes of the genotype effects in meta-
analyses to overcome these methodological differences. The rep-
lication of the genotype effects within each of the samples and
across study sites despite some procedural differences under-
scores the robustness of our findings.
(IV) All participants were screened for drug use within the
SCID-I interview, but we only obtained drug urine toxicologies
from our schizophrenia patients to rule out current drug use.
Thus, we could exclude acute illicit drug effects on PPI only in a
subset of the total subjects. However, given the strict inclusion
criteria, it is highly unlikely that a significant number of subjects
would have been taking drugs, and even less likely that a gene–
Table 4. Association of low PPI with the presence of the schizophrenia risk allele C of the TCF4 rs9960767 polymorphism in both investigated samples
Criterion for low PPI levelsa Samples Total n
PPI
deficit (n)
TCF4
C-allele (n)
PPI deficit
TCF4 C-allele (n)
Odds
ratio 95% CI pb
1 SD below normal London healthy controls 98 17 12 6 6.82 1.86–24.93 0.006
Bonn schizophrenia patients high-risk individuals 105 41 11 8 4.93 1.22–19.85 0.022
London Bonn 203 58 23 14 4.81 1.95–11.87 0.0009
1.5 SD below normal London healthy controls 98 9 12 3 4.44 0.95–20.89 0.078
Bonn schizophrenia patients high-risk individuals 105 32 11 5 2.07 0.58–7.35 0.304
London Bonn 203 41 23 8 2.38 0.93–6.07 0.093
Bold indicates statistical significance. CI, Confidence interval.
aThe healthy London sample refers to itself (mean PPI across 30 ms, 60 ms, and 120 ms SOA conditions: 30.8
 17.2% SD), whereas the schizophrenia spectrum Bonn sample refers to a normal population showing a mean PPI of 58.1%
(
21.7 SD) at an SOA of 120 ms measured with the same setup (Quednow et al., 2008a).
bFisher’s exact test.
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phenotype association that is observed in two independent sam-
ples could be accounted for by this.
(V) Finally, estimations of the genetic effect based on novel
association findings tend to be upwardly biased due to a phenom-
enon also known as the “winner’s curse” (Xiao and Boehnke,
2009). However, given that we replicated our finding in a second
sample and considering the fact that the effect size of TCF4 geno-
type effect seems to be one of the strongest genotype effects on
PPI reported so far (e.g., Quednow et al., 2008b, 2009, 2010;
Roussos et al., 2008a,b, 2009; Petrovsky et al., 2010), it is highly
likely that this effect will survive further investigation.
In conclusion, our results suggest that TCF4 variants could
play an important role in the development of diminished senso-
rimotor gating in schizophrenia. These deficits might arise from
developmental changes of brainstem nuclei. As subjects carrying
the TCF4 rs9960767 C-allele robustly showed diminished PPI
levels, an extended endophenotype including PPI and TCF4 ge-
notype status warrants testing as an early indicator for a develop-
ing psychosis (Prasad and Keshavan, 2008).
References
Anokhin AP, Heath AC, Myers E, Ralano A, Wood S (2003) Genetic influ-
ences on prepulse inhibition of startle reflex in humans. Neurosci Lett
353:45–48.
Armitage P (1955) Tests for linear trends in proportions and frequencies.
Biometrics 11:375–386.
Bland JM, Altman DG (2000) Statistics notes. The odds ratio. BMJ
320:1468.
Blumenthal TD (1999) Short lead interval startle modification. In: Startle
modification. Implications for neuroscience, cognitive sciences, and clin-
ical science (DawsonME, Schell AM, Bo¨hmelt AH, eds), pp 51–71. Cam-
bridge, UK: Cambridge UP.
Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle
reflex in schizophrenic patients. Arch Gen Psychiatry 49:206–215.
Braff DL, GeyerMA, SwerdlowNR (2001) Human studies of prepulse inhi-
bition of startle: normal subjects, patient groups, and pharmacological
studies. Psychopharmacology (Berl) 156:234–258.
Brzo´zka MM, Radyushkin K, Wichert SP, Ehrenreich H, Rossner MJ (2010)
Cognitive and sensorimotor gating impairments in transgenic mice over-
expressing the schizophrenia susceptibility gene Tcf4 in the brain. Biol
Psychiatry 68:33–40.
Cadenhead KS, Geyer MA, Braff DL (1993) Impaired startle prepulse inhi-
bition and habituation in patients with schizotypal personality disorder.
Am J Psychiatry 150:1862–1867.
Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL (2000) Modu-
lation of the startle response and startle laterality in relatives of schizo-
phrenic patients and in subjects with schizotypal personality disorder:
evidence of inhibitory deficits. Am J Psychiatry 157:1660–1668.
Cohen J (1988) Statistical power analysis for the behavioral sciences, Ed 2.
Hillsdale, NJ: Lawrence Erlbaum.
de Pontual L, Mathieu Y, Golzio C, Rio M, Malan V, Boddaert N, Soufflet C,
Picard C, Durandy A, Dobbie A, Heron D, Isidor B, Motte J, Newburry-
EcobR, Pasquier L, TardieuM,Viot G, Jaubert F,Munnich A, Colleaux L,
et al. (2009) Mutational, functional, and expression studies of the TCF4
gene in Pitt-Hopkins syndrome. HumMutat 30:669–676.
Fendt M, Li L, Yeomans JS (2001) Brain stem circuits mediating prepulse
inhibition of the startle reflex. Psychopharmacology (Berl) 156:216–224.
FloraA,Garcia JJ, Thaller C, ZoghbiHY (2007) The E-proteinTcf4 interacts
with Math1 to regulate differentiation of a specific subset of neuronal
progenitors. Proc Natl Acad Sci U S A 104:15382–15387.
Frommann I, Pukrop R, Brinkmeyer J, Bechdolf A, Ruhrmann S, Berning J,
Decker P, Riedel M, Mo¨ller HJ, Wo¨lwer W, Gaebel W, Klosterko¨tter J,
Maier W, Wagner M (2010) Neuropsychological profiles in different
at-risk states of psychosis: executive control impairment in the early—
and additionalmemory dysfunction in the late—prodromal state. Schizo-
phr Bull. Advance online publication. doi:10.1093/schbul/sbp155.
Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry:
etymology and strategic intentions. Am J Psychiatry 160:636–645.
GrahamFK (1975) Themore or less startling effects of weak prestimulation.
Psychophysiology 12:238–248.
Greenwood TA, Braff DL, Light GA, Cadenhead KS, Calkins ME, Dobie DJ,
Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH,
Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS,
Swerdlow NR, Tsuang DW, et al. (2007) Initial heritability analyses of
endophenotypic measures for schizophrenia: the consortium on the ge-
netics of schizophrenia. Arch Gen Psychiatry 64:1242–1250.
Ha¨fner H, Maurer K, Ruhrmann S, Bechdolf A, Klosterko¨tter J, Wagner M,
Maier W, Bottlender R, Mo¨ller HJ, Gaebel W, Wo¨lwer W (2004) Early
detection and secondary prevention of psychosis: facts and visions. Eur
Arch Psychiatry Clin Neurosci 254:117–128.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstro¨mKO (1991) The Fag-
erstrom test for nicotine dependence: a revision of the Fagerstrom toler-
ance questionnaire. Br J Addict 86:1119–1127.
Hedges LV, Olkin I (1985) Statistical methods formeta-analysis. New York:
Academic.
Hong LE, Wonodi I, Lewis J, Thaker GK (2008) Nicotine effect on prepulse
inhibition and prepulse facilitation in schizophrenia patients. Neuropsy-
chopharmacology 33:2167–2174.
Kay SR, Opler LA, Fiszbein A (1992) Positive and Negative Syndrome Scale
(PANSS). Manual. North Tonawanda, NY: Multi-Health Systems.
Koch M (1999) The neurobiology of startle. Prog Neurobiol 59:107–128.
Kumari V, Gray JA (1999) Smoking withdrawal, nicotine dependence and
prepulse inhibition of the acoustic startle reflex. Psychopharmacology
(Berl) 141:11–15.
Kumari V, Soni W, Mathew VM, Sharma T (2000) Prepulse inhibition of
the startle response in men with schizophrenia: effects of age of onset of
illness, symptoms, and medication. Arch Gen Psychiatry 57:609–614.
Kumari V, Das M, Zachariah E, Ettinger U, Sharma T (2005a) Reduced
prepulse inhibition in unaffected siblings of schizophrenia patients. Psy-
chophysiology 42:588–594.
Kumari V, Antonova E, Zachariah E, Galea A, Aasen I, Ettinger U, Mitter-
schiffthaler MT, Sharma T (2005b) Structural brain correlates of pre-
pulse inhibition of the acoustic startle response in healthy humans.
Neuroimage 26:1052–1058.
Li T, Li Z, Chen P, Zhao Q, Wang T, Huang K, Li J, Li Y, Liu J, Zeng Z, Feng
G, He L, Shi Y (2010) Common variants in major histocompatibility
complex region and TCF4 gene are significantly associated with schizo-
phrenia in Han Chinese. Biol Psychiatry 68:671–673.
Ludewig K, Geyer MA, Vollenweider FX (2003) Deficits in prepulse inhibi-
tion and habituation in never-medicated, first-episode schizophrenia.
Biol Psychiatry 54:121–128.
NeedAC,GeD,WealeME,Maia J, Feng S,Heinzen EL, ShiannaKV, YoonW,
Kasperaviciu te D, Gennarelli M, Strittmatter WJ, Bonvicini C, Rossi G,
Jayathilake K, Cola PA, McEvoy JP, Keefe RS, Fisher EM, St Jean PL,
Giegling I, et al. (2009) A genome-wide investigation of SNPs andCNVs
in schizophrenia. PLoS Genet 5:e1000373.
Parwani A, Duncan EJ, Bartlett E, Madonick SH, Efferen TR, Rajan R, Sanfi-
lipo M, Chappell PB, Chakravorty S, Gonzenbach S, Ko GN, Rotrosen JP
(2000) Impaired prepulse inhibition of acoustic startle in schizophrenia.
Biol Psychiatry 47:662–669.
PetrovskyN,QuednowBB, EttingerU, SchmechtigA,Mo¨ssner R,CollierDA,
Ku¨hnK-U,MaierW,WagnerM, Kumari V (2010) Sensorimotor gating
is associated with CHRNA3 polymorphisms in schizophrenia and healthy
volunteers. Neuropsychopharmacology 35:1429–1439.
Prasad KM, Keshavan MS (2008) Structural cerebral variations as useful
endophenotypes in schizophrenia: do they help construct “extended en-
dophenotypes”? Schizophr Bull 34:774–790.
Quednow BB, Ku¨hn KU, Beckmann K, Westheide J, Maier W, Wagner M
(2006a) Attenuation of the prepulse inhibition of the acoustic startle
response within and between sessions. Biol Psychol 71:256–263.
Quednow BB, Wagner M, Westheide J, Beckmann K, Bliesener N, Maier W,
Ku¨hn KU (2006b) Sensorimotor gating and habituation of the startle
response in schizophrenic patients randomly treated with amisulpride or
olanzapine. Biol Psychiatry 59:536–545.
Quednow BB, Frommann I, Berning J, Ku¨hn KU, Maier W, Wagner M
(2008a) Impaired sensorimotor gating of the acoustic startle response in
the prodrome of schizophrenia. Biol Psychiatry 64:766–773.
Quednow BB, Ku¨hn KU, Mo¨ssner R, Schwab SG, Schuhmacher A, Maier W,
WagnerM (2008b) Sensorimotor gating of schizophrenia patients is influ-
enced by 5-HT2A receptor polymorphisms. Biol Psychiatry 64:434–437.
QuednowBB, Schmechtig A, Ettinger U, PetrovskyN, Collier DA, Vollenweider
FX, Wagner M, Kumari V (2009) Sensorimotor gating depends on poly-
6690 • J. Neurosci., May 4, 2011 • 31(18):6684–6691 Quednow et al. • TCF4 and Sensorimotor Gating in Humans
morphisms of the serotonin-2A receptor and catechol-O-methyltransferase,
but not onneuregulin-1Arg38Gln genotype: a replication study.Biol Psychi-
atry 66:614–620.
QuednowBB,WagnerM,Mo¨ssnerR,MaierW,Ku¨hnKU (2010) Sensorimotor
gating of schizophrenia patients depends on catechol O-methyltransferase
Val158Met polymorphism. Schizophr Bull 36:341–346.
Redgrave P, Mitchell IJ, Dean P (1987) Descending projections from the supe-
rior colliculus in rat: a study using orthograde transport of wheatgerm-
agglutinin conjugated horseradish peroxidase. Exp Brain Res 68:147–167.
Ross SE, Greenberg ME, Stiles CD (2003) Basic helix-loop-helix factors in
cortical development. Neuron 39:13–25.
Roussos P, Giakoumaki SG, Bitsios P (2008a) The dopamine D(3) receptor
Ser9Gly polymorphism modulates prepulse inhibition of the acoustic
startle reflex. Biol Psychiatry 64:235–240.
Roussos P, Giakoumaki SG, Rogdaki M, Pavlakis S, Frangou S, Bitsios P
(2008b) Prepulse inhibition of the startle reflex depends on the catechol
O-methyltransferase Val158Met gene polymorphism. Psychol Med
38:1651–1658.
Roussos P, Giakoumaki SG, Bitsios P (2009) A risk PRODH haplotype af-
fects sensorimotor gating, memory, schizotypy, and anxiety in healthy
male subjects. Biol Psychiatry 65:1063–1070.
Soosaar A, Chiaramello A, Zuber MX, Neuman T (1994) Expression of
basic-helix-loop-helix transcription factor ME2 during brain develop-
ment and in the regions of neuronal plasticity in the adult brain. Brain Res
Mol Brain Res 25:176–180.
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D,
Werge T, Pietila¨inen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafs-
son O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T,
Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, et al. (2009) Common
variants conferring risk of schizophrenia. Nature 460:744–747.
Swerdlow NR, Koob GF (1987) Dopamine, schizophrenia, mania, and de-
pression: toward a unified hypothesis of cortico-striatopallido-thalamic
function. Behav Brain Sci 10:197–208.
Swerdlow NR, Hartman PL, Auerbach PP (1997) Changes in sensorimotor
inhibition across the menstrual cycle: implications for neuropsychiatric
disorders. Biol Psychiatry 41:452–460.
Swerdlow NR, Geyer MA, Braff DL (2001) Neural circuit regulation of pre-
pulse inhibition of startle in the rat: current knowledge and future chal-
lenges. Psychopharmacology (Berl) 156:194–215.
Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff DL
(2006) Startle gating deficits in a large cohort of patients with schizo-
phrenia: relationship to medications, symptoms, neurocognition, and
level of function. Arch Gen Psychiatry 63:1325–1335.
Uittenbogaard M, Chiaramello A (2000) Differential expression patterns of
the basic helix-loop-helix transcription factors during aging of themurine
brain. Neurosci Lett 280:95–98.
Vertes RP, Martin GF, Waltzer R (1986) An autoradiographic analysis of
ascending projections from the medullary reticular formation in the rat.
Neuroscience 19:873–898.
Whitlock MC (2005) Combining probability from independent tests:
the weighted Z-method is superior to Fisher’s approach. J Evol Biol
18:1368–1373.
Woolf NJ, Butcher LL (1989) Cholinergic systems in the rat brain: IV. De-
scending projections of the pontomesencephalic tegmentum. Brain Res
Bull 23:519–540.
Xiao R, Boehnke M (2009) Quantifying and correcting for the winner’s
curse in genetic association studies. Genet Epidemiol 33:453–462.
Zhuang Y, Cheng P, Weintraub H (1996) B-lymphocyte development is
regulated by the combined dosage of three basic helix-loop-helix genes,
E2A, E2–2, and HEB. Mol Cell Biol 16:2898–2905.
Zweier C, PeippoMM,Hoyer J, Sousa S, Bottani A, Clayton-Smith J, Reardon
W, Saraiva J, Cabral A, Gohring I, Devriendt K, de Ravel T, Bijlsma EK,
Hennekam RC, Orrico A, Cohen M, Dreweke A, Reis A, Nurnberg P,
Rauch A (2007) Haploinsufficiency of TCF4 causes syndromal mental
retardationwith intermittent hyperventilation (Pitt-Hopkins syndrome).
Am J Hum Genet 80:994–1001.
Quednow et al. • TCF4 and Sensorimotor Gating in Humans J. Neurosci., May 4, 2011 • 31(18):6684–6691 • 6691
